A lawsuit against pulse oximeter manufacturers and distributors is starting to create change. But experts say the FDA needs ...

The Centers for Medicare & Medicaid Services granted transitional pass-through (TPT) payment status to Medtronic and Recor Medical for renal denervation devices to treat high blood pressure.

Medtronic and Recor Medical, Inc. (and its parent company, Otsuka Medical Devices Co., Ltd.) separately and independently ...

Medtronic plc (NYSE:MDT ), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2025 on Tuesday, November 19, 2024. A ...

Medtronic announced new long-term data from the SPYRAL HTN-ON MED clinical trial of the company’s Symplicity Spyral renal ...

The Medtronic Symplicty Spyral renal denervation ... The approvals reflect CMS’s recognition of these devices as breakthrough technologies representing significant clinical advances in managing ...

Medtronic (NYSE:MDT) announced results from two studies evaluating the utility of atherectomy for peripheral endovascular interventions. The Total REALITY study retrospectively compared ...

(Courtesy of Medtronic) At the time, pacemakers were “crude devices,” with wires coming out of the person’s body and “they were susceptible like anything that uses wall power,” said ...

Medtronic plc added a second U.S. FDA pulsed field ablation (PFA) device approval to its scorecard with the agency’s greenlight for its Affera mapping and ablation system with the Sphere-9 catheter.